生物活性 | Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitiveaurorainhibitor withIC50s of116, 5, 1 nM foraurora A,aurora B,aurora C, respectively. Ilorasertib hydrochloride also is a potentVEGF,PDGFinhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][2]. |
IC50& Target[2] | Aurora C 1 nM (IC50) | Aurora B 7 nM (IC50) | Aurora B (Y156H) 12 nM (IC50) | Aurora A 120 nM (IC50) | PDGFRα 11 nM (IC50) | PDGFRβ 13 nM (IC50) | VEGFR1 1 nM (IC50) | VEGFR2 2 nM (IC50) | VEGFR3 43 nM (IC50) | FLT3 1 nM (IC50) | CSF-1R 3 nM (IC50) | c-KIT 20 nM (IC50) |
|
体外研究 (In Vitro) | Ilorasertib hydrochloride (0, 3, 10, 30 nM; 24 h) induces a concentration-dependent increase in the extent and number of H1299, H460 cells[2]. Ilorasertib hydrochloride (1-1000 nM) shows antiproliferative activity[2].
Cell Viability Assay[2] Cell Line: | H1299, H460 cells | Concentration: | 0, 3, 10, 30 nM | Incubation Time: | 24 h | Result: | Induced a concentration-dependent increase in the extent and number of cells exhibiting polyploidy with EC50S of 5, 10 nM for H1299, H460 cells, respectively. |
Cell Proliferation Assay[2] Cell Line: | MV-4-11, SEM, K562, HCT-15, SW620, H1299, H460 cells | Concentration: | 1-1000 nM | Incubation Time: | | Result: | Showed antiproliferative activity with IC50s of 0.3, 1, 103, 6, 6, 2, 2 nM for MV-4-11, SEM, K562, HCT-15, SW620, H1299, H460 cells, respectively. |
|
体内研究 (In Vivo) | Ilorasertib hydrochloride (6.25, 12.5, 25 mg/kg; p.o.) shows anti-tumor activity in MV-4-11 tumor-bearing SCID mice with TGI of 80%, 86%, 94% at 6.25, 12.5, 25 mg/kg, respectively[1]. Ilorasertib hydrochloride (6.25, 12.5, 25 mg/kg; p.o.) shows anti-tumor activity in SKM-1 tumor-bearing SCID mice with TGI of 38%, 59%, 80% at 6.25, 12.5, 25 mg/kg, respectively[1]. Ilorasertib hydrochloride (0, 3.75, 7.5, 15 mg/kg; i.p.) inhibits the histone H3 phosphorylation at 4-8 h in blood-borne tumor cells[2]. Ilorasertib hydrochloride (0.2 mg/kg; i.v.) shows anti-VEGF activity in mouse[2]. Ilorasertib hydrochloride (20 mg/kg; p.o.;once weekly for 3 weeks) shows anti-tumor activity in mouse[2].
Animal Model: | Female SCID/beige mice[2] | Dosage: | 25 mg/kg | Administration: | Subcutaneous minipump; 24 h | Result: | Inhibited the histone H3 phosphorylation and the tumor drug concentration associated with 50% inhibition of histone H3 phosphorylation. |
Animal Model: | 22-26 g, female NOD/SCID mice (xenograft model of multiple myeloma (KMS11))[2] | Dosage: | 20 mg/kg | Administration: | P.o.; once weekly for 3 weeks | Result: | Inhibited the tumor growth in mouse. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 41.67 mg/mL(79.37 mM;Need ultrasonic) 配制储备液 1 mM | 1.9048 mL | 9.5238 mL | 19.0476 mL | 5 mM | 0.3810 mL | 1.9048 mL | 3.8095 mL | 10 mM | 0.1905 mL | 0.9524 mL | 1.9048 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (3.96 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.96 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (3.96 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.96 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|